[{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inside A Startup\u2019s Pivot To Have AI Fight Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"HONG KONG","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Insilico Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AllianThera Biopharma Comes out Of Stealth and Collaborates on AI with Insilico Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"HONG KONG","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Huadong Medicine and Insilico Medicine Enter Co-Development Partnership to Advance Oncology Drug Discovery by Hitting Undruggable Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"HONG KONG","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insilico Begins First Human Trial of AI-Designed Fibrosis Drug","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"EQRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Insilico Medicine Announces Strategic Collaboration with EQRx to Jointly Advance AI-driven Drug Discovery, Development and Commercialization for Multiple Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"HONG KONG","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insilico Medicine Expands Synthetic Lethality Portfolio With Nomination Of A Preclinical Candidate Targeting MAT2A For The Treatment Of MTAP-deleted Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"BHR Partners","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,221.5 million","upfrontCash":"Undisclosed","newsHeadline":"Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"HONG KONG","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insilico Medicine Receives FDA Orphan Drug Designation For Generative AI Discovered and Designed Drug for Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insilico Medicine Announces IND Approval of Oral 3CLpro Inhibitor ISM3312 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Stemline Therapeutics","pharmaFlowCategory":"D","amount":"$512.0 million","upfrontCash":"$12.0 million","newsHeadline":"Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"}]
Find Clinical Drug Pipeline Developments & Deals by Insilico Medicine
Under the agreement, Stemline will have the global rights to develop and commercialize a novel, small molecule KAT6A inhibitor designed using Insilico’s AI platform, as a potential treatment for hormone sensitive cancers and other oncology indications.
Under the agreement, Insilico granted Exelixis an exclusive, worldwide license to develop and commercialize ISM3091, a best-in-class small molecule inhibitor of USP1, as a synthetic lethal target in the context of BRCA-mutated tumors, and other USP1-targeting compounds.
ISM3312 is a highly selective 3CLpro inhibitor with a novel molecular structure optimized from compounds designed by Chemistry42, Insilico’s generative chemistry AI platform for the treatment of COVID-19.
INS018_055 is the first anti-fibrotic small molecule inhibitor, generated by Insilico's Pharma.AI drug discovery platform, which targets major activated signaling cascades that significantly contribute to the pathogenesis idiopathic pulmonary fibrosis.
Under the terms of the agreement, the collaboration will leverage Insilico Medicine’s AI platform, Pharma.AI, to advance drug development candidates for up to six new targets.
Capital raised in the round will further bolster Insilico's financial position and fuel the growth of its advancing pipeline, including its lead program ISM001-55 (INS018_055) which is currently in a Phase I study, and continued development of its Pharma.AI platform.
Insilico's candidate demonstrated a favorable profile with good in vivo efficacy at low doses, efficient synthesis, and no need for co-administration with Ritonavir.
Preclinical candidate targeting methionine adenosyltransferase 2A (MAT2A) from AI-designed molecules for the treatment of methylthioadenosine phosphorylase (MTAP)-deleted cancers.
Insilico's PCC molecule, ISM025 demonstrated potential when targeted against a broad range of tumor lineages with HRD backgrounds. In vitro data showed potent anti-proliferation activity of the compound in BRCA-mutant tumor cells with excellent selectivity.
The collaboration will combine Insilico's Pharma.AI platform to advance de novo small molecule design and generation with EQRx's clinical development and commercialization expertise.